health innovations in horizon 2020: the framework ... · health innovations in horizon 2020: the...
TRANSCRIPT
Virginija Dambrauskaite, MD, PhD
Scientific Officer, Medical Research Unit, Health Directorate Directorate-General for Research & Innovation
European Commission
Health Innovations in Horizon 2020: the framework programme for research and innovation (2014-2020)
What Horizon 2020 is about
Responding to the economic crisis
Addressing people’s concerns
Strengthening the EU’s global position
Horizon 2020 timeline
From 30/11 Parliament and Council negotiations on the basis of the Commission proposals
On-going Parliament and Council negotiations on EU budget 2014-20 (including Horizon 2020)
By end 2013 Adoption of legislative acts by Parliament and Council on Horizon 2020
January 2014 Horizon 2020 starts; launch of first calls
2011
2012
2013
2014
More money for health research in times of austerity…?
Investing into the right research pays off:
Simpler, more personalised and cost-efficient technologies and treatments
Fewer ‘chronic patients’
New technologies, companies and markets
Higher share of radical innovation
Large returns on investment
New skilled jobs in high value-added sectors
Horizon 2020 and the Health, Demographic change and Wellbeing
challenge • Adapting to an ageing population
• Pursuing the path to more personalised medicine
• Harnessing and encouraging private sector capability
• Coordinating national efforts
• Expanding global cooperation
Health, Demographic change & wellbeing -the Commission's proposal for Horizon 2020
• Understanding health determinants
• Improving health promotion & disease prevention
• Developing effective screening programmes
• Improving the assessment of disease susceptibility
• Improving surveillance and preparedness
• Understanding disease
• Developing better preventive vaccines
• Improving diagnosis
• Using in-silico medicine for improving disease management and prediction
• Treating disease
• Transferring knowledge to clinical practice and scalable innovation actions
• Better use of health data
• Improving support for policy-making and regulation
• Active ageing, independent and assisted living
• Individual empowerment for self-management of health
• Promoting integrated care
• Optimising the efficiency and effectiveness of healthcare systems
• Reducing inequalities through evidence based decision making
• Dissemination of best practice, and innovative technologies and approaches.
The challenges ahead
• Cancer, chronic and degenerative diseases gain importance in the context of the ageing population
• More than 70% of healthcare spending on chronic diseases
• Wanted: ways of keeping our healthcare costs stable and our healthcare systems running
• EU must catch up with global health innovation leaders and keep its biomedical industry
The FP7 Health Programme
The largest multi-national fund:
to fund collaborative research
to fund international consortia and public-private partnerships
to fund excellent research and innovation in applied fields
involving leading players from Europe and across the globe
to tackle key health challenges which are too important or large for any one country to address alone
FP7 Health – state of play
3.3 billion EUR currently invested in 713 on-going projects
Some 2,900 organisations from 122 countries involved
Leading role in 6 international research consortia
1 billion EUR investment in Europe's largest public-private initiative for better and safer medicines
IMI is the world-largest Public-Private Partnership in health sciences research
Public Private Partnerships – the Innovative Medicines Initiative
10 regulators
17 patient
org
92 SMEs
508 Academic
& research
teams
341 EFPIA teams
603 million EUR IMI JU cash
contribution
600 million EUR EFPIA in kind contribution
~ 3500 researchers > 200 publications
Imaging
biomarkers:
the next
generation of
surrogate end
points?
Models for target
validation of
breast, prostate
and lung cancers
IMI State of play
Enhancing the innovation impact of results
Boosting the translation of health research projects' results into innovative applications for health (Inno-2).
Aimed at exploiting results from
projects funded within FP6 and FP7
Providing the viability of new methods, technologies, models or prototypes
Up to 5 patners and € 6 million
SMEs in the driving seat
Bridging the gap between successful prior research and the earlierst stage of a marketable innovation
€ 95 million
© Sergej Khackimullin #32849829 Source: Fotolia.com
FP7 Health – The concept of social innovation
To promote better quality of life and improved well-being for the elderly through innovative holistic approaches that meet social needs and create new social relationships
Examples: The development of a personalised strategy for reducing risks to
developing dementia.
The development of personalized electronic tools for effective
virtual rehabilitation environment after a stroke.
The development of an approach for health literacy for ageing
people, through the use of modern media and e-health
applications.
The development of social innovations to improve the quality of life
and well-being of older people.
Novel solutions to overcome bottlenecks to innovation
• Horizon2020 aims to optimise the efficiency and
effectiveness of health systems through the development of health technology assessment, health economics and innovative technologies and approaches in the healthcare sector.
Identification of the major bottlenecks to innovation in the area of research on health care systems
Finding solutions for creating a sustainable, cost effective and efficient health care system
Empowering people, driving change
• Behavioural change is critical to the prevention, management and treatment of many important health conditions and improves health outcomes, as well as cost savings to healthcare systems.
Finding the best approach to empower people to make the behavioural changes required
Scaling up innovative solutions
• Horizon 2020 aims to scale up innovative solutions to overcome the challenges and barriers to preventive health and to ensure that innovative and effective products reach the market.
Attracting stakeholders such as SMEs, industry and other sectors to innovation and ensure they become part of the solution
Implementing Open Innovation
• Horizon 2020 will support the full spectrum of activities throughout the research and innovation cycle – from knowledge and technology transfer to large scale demonstration actions, leading to scalable solutions for Europe and beyond.
Implementing Open Innovation in Horizon 2020
Consider the benefits and risks of Open Innovation in EU health research
Collaborative projects
Simpler
• Simpler programme architecture, a single set of rules
• Easy to use cost reimbursement model: one unique funding rate
• Less paperwork in preparing proposals
• Reduce time to grant by 100 days
More inclusive
• More support for innovation and activities close to the market
• Strong focus on creating business opportunities
Special support for SMEs
• ~5 billion EUR in H2020
• Inspired by the US model "SBIR"
• Challenge driven, bottom up
• A single company can be funded
• 3 phases / 3 entry points:
• Concept and feasibility assessment
• R&D, demonstration, market replication
• Commercialisation
In the pipeline: public-private partnership for innovative health
research
Based on the successes of the Innovative Medicines Initiative (IMI)
Legislative proposals only after Horizon 2020 approval
Organisation and structure to be defined
Your view matters (public consultation closed on 4th October)
Thank you!